Abstract
Background Bariatric surgery induces significant shifts in the gut microbiota which could potentially contribute to weight loss and metabolic benefits. The aim of this study was to characterize a microbial signature following Roux-en-Y Gastric bypass (RYGB) surgery using novel and existing gut microbiota sequence data.
Results We generated 16S rRNA gene and metagenomic sequences from fecal samples from patients undergoing RYGB surgery (n = 61 for 16S rRNA gene and n = 135 for metagenomics). We compared these data with three smaller publicly available 16S rRNA gene and one metagenomic datasets from patients who also underwent RYGB surgery. Mixed linear models and machine learning approaches were used to examine the presence of a common microbial signature across studies. Comparison of our new sequences with previous longitudinal studies revealed strikingly similar profiles in both fecal microbiota composition (r = 0.41 ± 0.10; p < 0.05) and metabolic pathways (r = 0.70 ± 0.05; p < 0.001) early after surgery across multiple datasets. Machine learning approaches revealed that the replicable gut microbiota signature associated with RYGB surgery could be used to discriminate pre- and post-surgical samples. Opportunistic pathogen abundance also increased post-surgery in a consistent manner across cohorts.
Conclusion Our study reveals a robust microbial signature involving many commensal and pathogenic taxa and metabolic pathways early after RYGB surgery across different studies and sites. Characterization of the effects of this robust microbial signature on outcomes of bariatric surgery could provide insights into the development of microbiome-based interventions for predicting or improving outcomes following surgery.
Trial Registration clinicaltrials.gov, number NCT03065426. Registered 27 February 2017, https://www.clinicaltrials.gov/ct2/show/NCT03065426
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03065426
Funding Statement
This project was supported by Grant NIH R01 DK112585-01 (PIs: Steffen and Heinberg)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards Cleveland Clinic: #16-1460, Sanford Health: #00001409 and North Dakota State University: #PH17112
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequences have been deposited at in the NCBI SRA (National Center for Biotechnology information Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra) under BiopProject PRJNA668357 and PRJNA668472. Sequences from other datasets that are included in this study can be found at SRA under BioProject PRJNA395660, PRJNA612042, and PRJEB14082, PRJEB12947. Scripts and materials to reproduce all figures and tables are available at https://github.com/FarnazFouladi/RYGB_IntegratedAnalysis2020.
List of abbreviations
- RYGB
- Roux-en-Y Gastric bypass
- SG
- Sleeve Gastrectomy
- ASVs
- Amplicon Sequence Variants
- FDR
- False Discovery Rate
- LASSO
- Least Absolute Shrinkage and Selection Operator
- AUROC
- Area Under the Receiver Operating Characteristic Curve
- LOSO
- Leave One Study Out (LOSO)